Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy

Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy

We tested the hypothesis, that proliferative activity of hematopoietic stem cells has impact on survival in newly diagnosed patients with myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (AML). RNA expression profiles of CD34(+) cells were analyzed in 125 MDS patients and compared...

Full description

Bibliographic Details
Main Authors:	Radujkovic, A, Dietrich, S, Andrulis, M, Benner, A, Longerich, T, Pellagatti, A, Nanda, K, Giese, T, Germing, U, Baldus, S, Boultwood, J, Ho, A, Dreger, P, Luft, T
Format:	Journal article
Language:	English
Published:	Wiley 2016

Similar Items

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.
by: Fernandez-Mercado, M, et al.
Published: (2013)

SF3B1 mutant myelodysplastic syndrome: Recent advances
by: Pellagatti, A, et al.
Published: (2020)

Comparison of cytomorphology and histomorphology in myelodysplastic syndromes
by: Kathrin Nachtkamp, et al.
Published: (2024-04-01)

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
by: Pellagatti, A, et al.
Published: (2016)

Gene expression profiling in the myelodysplastic syndromes.
by: Pellagatti, A, et al.
Published: (2005)

Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia.
by: Boultwood, J, et al.
Published: (2004)

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation.
by: Liberante, F, et al.
Published: (2013)

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation
by: Liberante, F, et al.
Published: (2013)

Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia.
by: Pellagatti, A, et al.
Published: (2014)

Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia
by: Pellagatti, A, et al.
Published: (2014)

The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
by: Boultwood, J, et al.
Published: (2014)

Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia
by: Boultwood, J, et al.
Published: (2009)

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
by: Armstrong, R, et al.
Published: (2017)

Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation
by: Mark-Alexander Schwarzbich, et al.
Published: (2022-02-01)

Frequent Mutation of the Polycomb-Associated Gene ASXL1 In Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
by: Fernandez-Mercado, M, et al.
Published: (2010)

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
by: Bernard, E, et al.
Published: (2020)

Mutations in PTPN11 are rare in adult myelodysplastic syndromes and acute myeloid leukemia.
by: Watkins, F, et al.
Published: (2004)

Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.
by: Boultwood, J, et al.
Published: (2010)

COMPREHENSIVE ANALYSIS OF MUTATION STATUS, GENE EXPRESSION PROFILES, BLOOD AND BONE MARROW COUNTS AND OUTCOME IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
by: Pellagatti, A, et al.
Published: (2014)

Neutrophil PRV-1 gene expression in myeloproliferative, myelodysplastic and reactive blood disorders
by: Zhang, J, et al.
Published: (2004)

Differential profile of CDKN1A and TP53 expressions in bone marrow mesenchymal stromal cells from myeloid neoplasms
by: Matheus Rodrigues Lopes, et al.

Clonality in the myelodysplastic syndromes.
by: Boultwood, J, et al.
Published: (2001)

Bone marrow–confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia
by: Yang Mei, et al.
Published: (2022-09-01)

Genetic and epigenetic alterations of bone marrow stromal cells in myelodysplastic syndrome and acute myeloid leukemia patients
by: Yonggoo Kim, et al.
Published: (2015-03-01)

Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia.
by: Watson, A, et al.
Published: (2011)

Molecular pathogenesis of the myelodysplastic syndromes
by: Boultwood, J, et al.
Published: (1999)

Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.
by: Pellagatti, A, et al.
Published: (2013)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
by: Annika Kasprzak, et al.
Published: (2022-04-01)

Gene Expression Profiling of CD34(+) Cells in Patients with Myelodysplastic Syndromes
by: Pellagatti, A, et al.
Published: (2008)

Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component
by: Victoria Platte, et al.
Published: (2022-12-01)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q)
by: Pellagatti, A, et al.
Published: (2005)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
by: Pellagatti, A, et al.
Published: (2009)

Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview
by: Andrea Kuendgen, et al.
Published: (2021-11-01)

Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
by: Olga Kouroukli, et al.
Published: (2022-11-01)

Telomere length in myelodysplastic syndromes.
by: Boultwood, J, et al.
Published: (1995)

L-leucine increases translation of RPS14 and LARP1 in erythroblasts from del(5q) myelodysplastic syndrome patients
by: Bello, E, et al.
Published: (2018)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
by: Pellagatti, A, et al.
Published: (2010)

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.
by: Jadersten, M, et al.
Published: (2005)

Hyperfibrinogenemia as a Poor Prognostic Indicator in Myelodysplastic Syndrome
by: Shi C, et al.
Published: (2022-06-01)

Gene expression profiling in 5q-syndrome and myelodysplastic syndromes.
by: Pellagatti, A, et al.
Published: (2003)